1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 63629-8846
  5. Product Images: Rivastigmine Transdermal System

Product Images Rivastigmine Transdermal System

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 63629-8846 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - lbl636298846

Label - lbl636298846

This is a description of Rivastigmine Transdermal System with 13.3 mg per 24 hours, sold in a 30 system pack. It provides instructions for use, including wearing only one patch at a time, changing the patch every 24 hours, and not cutting it. It also warns to keep out of reach of children and that it's only for transdermal use. The product should be stored at a temperature range of 15°C-30°C and the NDC code is 63629-8846-1.*

Chemical Structure - rivastigmine 01

Chemical Structure - rivastigmine 01

Figure 1 - rivastigmine 02

Figure 1 - rivastigmine 02

Figure 2 - rivastigmine 03

Figure 2 - rivastigmine 03

This text shows the concentration of Rivastigmine in ng/mL for different doses of the drug (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) and the number of participants (n) in each group (19, 22, and 22, respectively). It appears to be part of a study or clinical trial.*

Figure 3 - rivastigmine 04

Figure 3 - rivastigmine 04

Figure 4 - rivastigmine 05

Figure 4 - rivastigmine 05

Figure 5 - rivastigmine 06

Figure 5 - rivastigmine 06

Figure 6 - rivastigmine 07

Figure 6 - rivastigmine 07

Figure 7 - rivastigmine 08

Figure 7 - rivastigmine 08

This is a statistical analysis report comparing the efficacy of two treatments using LS mean diff and improvement. The treatments are Rivastigmine Transdermal System 15 cm² and Rivastigmine Transdermal System 5 cm² over 8, 16 and 24 weeks. The report provides statistical significance (p-values) for the analysis. The LS means and standard errors are also given.*

Figure 8 - rivastigmine 09

Figure 8 - rivastigmine 09

This is a description of a clinical study that evaluated the effects of Rivastigmine Transdermal System (15 cm2 and 5 cm2) on cognitive function over a period of 16 weeks. The study used a statistical analysis of covariance model to determine least squares means (LS means) and standard errors of the LS means (STE) adjusted for pooled center and baseline. The study results indicate that the treatment did not show statistical significance in improving cognitive function at a level of 0.05.*

Figure A - rivastigmine 10

Figure A - rivastigmine 10

Figure B - rivastigmine 11

Figure B - rivastigmine 11

Figure C - rivastigmine 12

Figure C - rivastigmine 12

Figure D - rivastigmine 13

Figure D - rivastigmine 13

Figure E - rivastigmine 14

Figure E - rivastigmine 14

Figure F - rivastigmine 15

Figure F - rivastigmine 15

Figure G - rivastigmine 16

Figure G - rivastigmine 16

Figure H - rivastigmine 17

Figure H - rivastigmine 17

This appears to be a set of instructions for discarding a patch, which should be folded with its sticky sides together and placed in the trash. The user is instructed to first fold the patch, and then place it in an empty pouch (that they have saved). Finally, there is a cautionary note to keep the patch away from children and pets.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.